- Home
- BCLI vs CGTX Comparison
BCLI vs CGTX Comparison
Compare BCLI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- CGTX
- Stock Information
- Founded
- BCLI 2000
- CGTX 2007
- Country
- BCLI United States
- CGTX United States
- Employees
- BCLI N/A
- CGTX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- CGTX Health Care
- Exchange
- BCLI Nasdaq
- CGTX Nasdaq
- Market Cap
- BCLI 13.5M
- CGTX 16.1M
- IPO Year
- BCLI N/A
- CGTX 2021
- Fundamental
- Price
- BCLI $1.89
- CGTX $0.68
- Analyst Decision
- BCLI Strong Buy
- CGTX Strong Buy
- Analyst Count
- BCLI 1
- CGTX 6
- Target Price
- BCLI $30.00
- CGTX $8.30
- AVG Volume (30 Days)
- BCLI 109.6K
- CGTX 18.9M
- Earning Date
- BCLI 11-14-2024
- CGTX 11-13-2024
- Dividend Yield
- BCLI N/A
- CGTX N/A
- EPS Growth
- BCLI N/A
- CGTX N/A
- EPS
- BCLI N/A
- CGTX N/A
- Revenue
- BCLI N/A
- CGTX N/A
- Revenue This Year
- BCLI N/A
- CGTX N/A
- Revenue Next Year
- BCLI N/A
- CGTX N/A
- P/E Ratio
- BCLI N/A
- CGTX N/A
- Revenue Growth
- BCLI N/A
- CGTX N/A
- 52 Week Low
- BCLI $1.05
- CGTX $0.34
- 52 Week High
- BCLI $11.85
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- BCLI 44.80
- CGTX 51.83
- Support Level
- BCLI $1.90
- CGTX $0.67
- Resistance Level
- BCLI $2.17
- CGTX $0.76
- Average True Range (ATR)
- BCLI 0.18
- CGTX 0.08
- MACD
- BCLI -0.05
- CGTX -0.02
- Stochastic Oscillator
- BCLI 4.76
- CGTX 9.12
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.